Cargando…

Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)

OBJECTIVES: In this study the concordance between the Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score 28-joint count (DAS28) was investigated in a clinical routine outpatient setting. PATIENTS AND METHODS: A sample of 150 adult patients with stable RA treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boone, Niels W., Teeuwisse, Patty, van der Kuy, Paul-Hugo, Janknegt, Rob, Landewé, Robert B. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551679/ https://www.ncbi.nlm.nih.gov/pubmed/26339563 http://dx.doi.org/10.1186/s40064-015-1247-5

Ejemplares similares

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
por: Boone, Niels W., et al.
Publicado: (2019)

Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
por: Boone, Niels W, et al.
Publicado: (2019)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
por: Rigby, William F. C., et al.
Publicado: (2017)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Saudi cultural adaptation of the “compliance questionnaire of Rheumatology” for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
por: Aljohani, Roaa, et al.
Publicado: (2021)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
por: Cho, Soo-Kyung, et al.
Publicado: (2017)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
por: Karadeniz, Hazan, et al.
Publicado: (2022)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

The Impact of Low-Dose Disease-modifying Anti-rheumatics Drugs (DMARDs) on Bone Mineral Density of Premenopausal Women in Early Rheumatoid Arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2016)

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
por: Peterson, Jeffrey D, et al.
Publicado: (2010)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
por: Richter, A, et al.
Publicado: (2016)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment
por: Miwa, Yusuke, et al.
Publicado: (2017)

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs
por: Kalweit, Maria, et al.
Publicado: (2023)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
por: Zago, Basiru Ahmad, et al.
Publicado: (2020)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
por: Marasco, Emiliano, et al.
Publicado: (2023)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs
por: Thomas, Konstantinos, et al.
Publicado: (2017)

Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study
por: Bellan, Mattia, et al.
Publicado: (2022)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Seronegative rheumatic arthritis has milder inflammation and bone erosion in an ultrasound study of disease-modifying anti-rheumatic drugs (DMARDs)-naïve Chinese cohort
por: Lin, Dongfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vu3d900d561878jcs55lqqcrcu